Published in Circulation on September 14, 2010
Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium. J Thorac Cardiovasc Surg (2015) 2.43
Stromal cell-derived factor-1 promoted angiogenesis and inflammatory cell infiltration in aneurysm walls. J Neurosurg (2013) 1.41
Stem cell recruitment after injury: lessons for regenerative medicine. Regen Med (2012) 1.14
Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis. J Pharmacol Exp Ther (2012) 1.12
Overexpression of angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS One (2012) 1.06
Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol (2012) 1.04
Transplantation of platelet gel spiked with cardiosphere-derived cells boosts structural and functional benefits relative to gel transplantation alone in rats with myocardial infarction. Biomaterials (2012) 1.00
Spliced stromal cell-derived factor-1α analog stimulates endothelial progenitor cell migration and improves cardiac function in a dose-dependent manner after myocardial infarction. J Thorac Cardiovasc Surg (2010) 0.95
Intramyocardial injection of platelet gel promotes endogenous repair and augments cardiac function in rats with myocardial infarction. J Am Coll Cardiol (2012) 0.95
Stem cell sources for vascular tissue engineering and regeneration. Tissue Eng Part B Rev (2012) 0.91
Cell therapy with embryonic stem cell-derived cardiomyocytes encapsulated in injectable nanomatrix gel enhances cell engraftment and promotes cardiac repair. ACS Nano (2014) 0.89
Homing of stem cells to ischemic myocardium. Am J Transl Res (2013) 0.86
Addition of mesenchymal stem cells enhances the therapeutic effects of skeletal myoblast cell-sheet transplantation in a rat ischemic cardiomyopathy model. Tissue Eng Part A (2014) 0.85
Rehmannia glutinosa extract activates endothelial progenitor cells in a rat model of myocardial infarction through a SDF-1 α/CXCR4 cascade. PLoS One (2013) 0.85
Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function. J Thorac Cardiovasc Surg (2014) 0.85
Preclinical evaluation of the engineered stem cell chemokine stromal cell-derived factor 1α analog in a translational ovine myocardial infarction model. Circ Res (2013) 0.83
Biomaterial applications in cardiovascular tissue repair and regeneration. Expert Rev Cardiovasc Ther (2012) 0.83
A modified approach to induce predictable congestive heart failure by volume overload in rats. PLoS One (2014) 0.82
Normalization of postinfarct biomechanics using a novel tissue-engineered angiogenic construct. Circulation (2013) 0.82
Myocardial restoration: is it the cell or the architecture or both? Cardiol Res Pract (2012) 0.79
Stem cells for cardiac repair: an introduction. J Geriatr Cardiol (2013) 0.79
Activation of protein kinase C ε enhanced movement ability and paracrine function of rat bone marrow mesenchymal stem cells partly at least independent of SDF-1/CXCR4 axis and PI3K/AKT pathway. Int J Clin Exp Med (2015) 0.78
Spatially oriented, temporally sequential smooth muscle cell-endothelial progenitor cell bi-level cell sheet neovascularizes ischemic myocardium. Circulation (2013) 0.78
Diastolic ventricular support with cardiac support devices: an alternative approach to prevent adverse ventricular remodeling. Heart Fail Rev (2013) 0.78
Loss of Sirt3 limits bone marrow cell-mediated angiogenesis and cardiac repair in post-myocardial infarction. PLoS One (2014) 0.77
Vascularization of three-dimensional engineered tissues for regenerative medicine applications. Acta Biomater (2016) 0.76
Fn14 is regulated via the RhoA pathway and mediates nuclear factor-kappaB activation by Angiotensin II. Am J Transl Res (2016) 0.75
VEGF treatment promotes bone marrow-derived CXCR4(+) mesenchymal stromal stem cell differentiation into vessel endothelial cells. Exp Ther Med (2017) 0.75
A Tissue-Engineered Chondrocyte Cell Sheet Induces Extracellular Matrix Modification to Enhance Ventricular Biomechanics and Attenuate Myocardial Stiffness in Ischemic Cardiomyopathy. Tissue Eng Part A (2015) 0.75
Overexpression of protein kinase C ɛ improves retention and survival of transplanted mesenchymal stem cells in rat acute myocardial infarction. Cell Death Dis (2016) 0.75
Strategy to Prime the Host and Cells to Augment Therapeutic Efficacy of Progenitor Cells for Patients with Myocardial Infarction. Front Cardiovasc Med (2016) 0.75
Zn(II) released from zinc oxide nano/micro particles suppresses vasculogenesis in human endothelial colony-forming cells. Toxicol Rep (2015) 0.75
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res (1999) 11.32
Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med (2001) 10.36
Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation (2002) 6.50
Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol (2005) 4.67
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation (2007) 2.88
Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation (2008) 2.22
Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via "imported" nitric oxide synthase activity. Circulation (2005) 2.18
Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol (2008) 2.16
Endothelial cell coculture within tissue-engineered cardiomyocyte sheets enhances neovascularization and improves cardiac function of ischemic hearts. Circulation (2008) 1.95
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thorac Surg (2006) 1.82
Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol (2003) 1.52
Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation (2002) 1.43
Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol (1997) 1.31
Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac Cardiovasc Surg (2005) 1.20
Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2. J Thorac Cardiovasc Surg (2007) 1.07
Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther (2007) 1.06
Echocardiographic assessment of cardiac structure and function in rats. Heart Lung Circ (2002) 1.05
Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery (1996) 1.00
Safety and efficacy of peripheral blood progenitor cell mobilization and collection in patients with advanced coronary heart disease. J Clin Apher (2006) 0.87
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 7.94
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2012) 6.94
Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med (2013) 6.21
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol (2006) 3.78
Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med (2015) 3.11
Saddle-shape annuloplasty increases mitral leaflet coaptation after repair for flail posterior leaflet. Ann Thorac Surg (2011) 2.42
Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant (2008) 2.32
Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J (2007) 2.12
The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta (2007) 2.09
Antegrade thoracic stent grafting during repair of acute DeBakey I dissection prevents development of thoracoabdominal aortic aneurysms. Ann Thorac Surg (2009) 1.95
Progress in mitral valve disease: understanding the revolution. J Cardiothorac Vasc Anesth (2009) 1.92
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann Thorac Surg (2006) 1.82
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2012) 1.80
Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J Biol Chem (2003) 1.64
Emergency extracorporeal life support for asphyxic status asthmaticus. Respir Care (2007) 1.59
Significance of malperfusion syndromes prior to contemporary surgical repair for acute type A dissection: outcomes and need for additional revascularizations. Eur J Cardiothorac Surg (2007) 1.59
Nitrogen balance and delta15N: why you're not what you eat during nutritional stress. Rapid Commun Mass Spectrom (2005) 1.55
Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway. Mol Cell Proteomics (2009) 1.52
Advances in the treatment of acute type A dissection: an integrated approach. Ann Thorac Surg (2002) 1.52
Transmyocardial revascularization to enhance myocardial vasculogenesis and hemodynamic function. J Thorac Cardiovasc Surg (2008) 1.49
Ascending aortic cannulation in acute type a dissection repair. Ann Thorac Surg (2013) 1.49
Who needs an RVAD in addition to an LVAD? Cardiol Clin (2011) 1.46
Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. J Thorac Cardiovasc Surg (2009) 1.44
Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. Biochem J (2005) 1.40
Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing pathogenic PrP mutations. J Biol Chem (2005) 1.39
Left main coronary embolism. J Invasive Cardiol (2006) 1.39
Molecular distinction between pathogenic and infectious properties of the prion protein. J Virol (2003) 1.38
Apelin has in vivo inotropic effects on normal and failing hearts. Circulation (2004) 1.37
Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation (2006) 1.32
Prion protein repeat expansion results in increased aggregation and reveals phenotypic variability. Mol Cell Biol (2007) 1.31
Nitrogen balance and delta15N: why you're not what you eat during pregnancy. Rapid Commun Mass Spectrom (2004) 1.29
Fate of the residual distal and proximal aorta after acute type a dissection repair using a contemporary surgical reconstruction algorithm. Ann Thorac Surg (2007) 1.26
Prion protein at the crossroads of physiology and disease. Trends Neurosci (2011) 1.26
Computational protein design to reengineer stromal cell-derived factor-1α generates an effective and translatable angiogenic polypeptide analog. Circulation (2011) 1.20
Outcomes of the RESTOR-MV Trial (Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve). J Am Coll Cardiol (2010) 1.20
Stromal cell-derived factor and granulocyte-monocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. J Thorac Cardiovasc Surg (2005) 1.20
Ethyl pyruvate preserves cardiac function and attenuates oxidative injury after prolonged myocardial ischemia. J Thorac Cardiovasc Surg (2004) 1.19
An N-terminal fragment of the prion protein binds to amyloid-β oligomers and inhibits their neurotoxicity in vivo. J Biol Chem (2013) 1.18
Bax deletion prevents neuronal loss but not neurological symptoms in a transgenic model of inherited prion disease. Proc Natl Acad Sci U S A (2004) 1.18
Robot-assisted pharyngeal and laryngeal microsurgery: results of robotic cadaver dissections. Laryngoscope (2005) 1.17
Dimerization of F0F1ATP synthase from bovine heart is independent from the binding of the inhibitor protein IF1. Biochim Biophys Acta (2002) 1.14
Biochemical analysis of MST1 kinase: elucidation of a C-terminal regulatory region. Biochemistry (2008) 1.14
Minimally invasive approach provides at least equivalent results for surgical correction of mitral regurgitation: a propensity-matched comparison. J Thorac Cardiovasc Surg (2013) 1.13
Neurotoxic mutants of the prion protein induce spontaneous ionic currents in cultured cells. J Biol Chem (2010) 1.12
A novel, drug-based, cellular assay for the activity of neurotoxic mutants of the prion protein. J Biol Chem (2009) 1.11
Outcomes using extracorporeal life support for adult respiratory failure due to status asthmaticus. ASAIO J (2009) 1.10
Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during prion infection. J Biol Chem (2003) 1.10
Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent. Virology (2008) 1.10
Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thorac Surg (2013) 1.09
Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation (2002) 1.08
Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials Network. J Thorac Cardiovasc Surg (2011) 1.08
Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2. J Thorac Cardiovasc Surg (2007) 1.07
Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: a novel clinical biomarker. Ann Thorac Surg (2011) 1.07
Adenosine A₂A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg (2011) 1.07
Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. J Neurosci (2005) 1.07
A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominant-negative inhibitor of PrPSc formation. J Biol Chem (2011) 1.07
Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities. J Neurosci (2008) 1.07
Three-dimensional echocardiographic analysis of mitral annular dynamics: implication for annuloplasty selection. Circulation (2012) 1.06
Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. Cell Mol Biol Lett (2006) 1.06
Surgical revision after percutaneous mitral repair with the MitraClip device. Ann Thorac Surg (2010) 1.05
Blocking the development of postischemic cardiomyopathy with viral gene transfer of the apoptosis repressor with caspase recruitment domain. J Thorac Cardiovasc Surg (2003) 1.05
Robotic microlaryngeal surgery: a technical feasibility study using the daVinci surgical robot and an airway mannequin. Laryngoscope (2005) 1.05
Retrograde and antegrade cerebral perfusion: results in short elective arch reconstructive times. Ann Thorac Surg (2010) 1.04
Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg (2005) 1.04
Non-infectious aggregates of the prion protein react with several PrPSc-directed antibodies. J Neurochem (2008) 1.04
An N-terminal polybasic domain and cell surface localization are required for mutant prion protein toxicity. J Biol Chem (2011) 1.03
GFP-tagged prion protein is correctly localized and functionally active in the brains of transgenic mice. Neurobiol Dis (2004) 1.02
Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans. Proc Natl Acad Sci U S A (2007) 1.02
Postoperative right ventricular failure after left ventricular assist device placement is predicted by preoperative echocardiographic structural, hemodynamic, and functional parameters. J Card Fail (2013) 1.02
Paratracheal air cysts using low-dose screening chest computed tomography: clinical significance and imaging findings. Jpn J Radiol (2011) 1.02
Prion neurotoxicity: insights from prion protein mutants. Curr Issues Mol Biol (2009) 1.02
Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods (2010) 1.01
Acute myocardial rescue with endogenous endothelial progenitor cell therapy. Heart Lung Circ (2010) 1.01
Visualization of prion infection in transgenic mice expressing green fluorescent protein-tagged prion protein. J Neurosci (2005) 0.99